Thanks, Did any one see this.......
------------------------------------------------------------------------
Thursday September 18 10:07 AM EDT
Company Press Release
VIVUS Appoints Carol D. Karp Vice President, Regulatory Affairs
MENLO PARK, Calif.--(BW HealthWire)--Sept. 18, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced the appointment of Carol D. Karp to the newly created position of vice president, regulatory affairs. Ms. Karp, who has 18 years of experience in the pharmaceutical industry, was most recently executive director of regulatory affairs at Cygnus, Inc.
``We are very pleased to have Carol join our management team,'' said Leland F. Wilson, president and CEO. ``Her international experience in regulatory affairs will be a valuable asset as we focus our efforts for MUSE(R) (alprostadil) outside the United States to support the international marketing agreements we have in place with partners Astra AB and Janssen Pharmaceutica.''
At Cygnus, Ms. Karp was responsible for all regulatory filings and contacts with the Food and Drug Administration (FDA) and other local and foreign regulatory agencies in regard to transdermal, diagnostic and consumer products. In her eight years at Cygnus, Ms. Karp established the regulatory affairs department and quality assurance functions and played a key role in acquiring certification for a commercial manufacturing facility. Prior to her tenure at Cygnus, Ms. Karp held various positions at Janssen Pharmaceutica, a subsidiary of Johnson & Johnson, from 1979 to 1989, most recently as assistant director, regulatory affairs. Ms. Karp completed postgraduate studies in biochemistry from New York University and postgraduate studies in business administration from Fairleigh-Dickinson University. She holds a B.A. degree in biology from the University of Rochester.
Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra.
------------------------------------------------------------------------
Contact:
VIVUS, Inc.
Nina W. Ferrari/David Yntema, 415/325-5511
IR@VIVUS.com |
